Biodesix price to book ratio BDSX

Market value divided by the book value of the company's net assets, since 2021.

Today, Oct 23, 2026: 24.4×
6-year median: 8.4×
Against its 6-year history: 81st; percentile: 0 is its lowest day, 100 its highest
6-year range: 2.6× to 58.4×
Peer median: 2.9×

Biodesix's price to book ratio is 24.4× as of Oct 23, 2026.

That is above its 6-year median of 8.4×, higher than on 81% of days in the last 6 years.

Over that time it ranged from 2.6× in Apr 2022 to 58.4× in Aug 2025.

The median for 10 healthcare stocks of a similar size is 2.9×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	24.4×	15.7×	33.7×
2025	44.0×	2.6×	58.4×
2024	7.7×	6.4×	33.4×
2023	27.2×	5.9×	27.2×
2022	5.3×	2.6×	14.4×
2021	8.9×	6.9×	14.4×

Against its peers

Companies in Healthcare nearest Biodesix's size, closest first, today.

Company	Price to book ratio
BDSXBiodesix	24.4×
ELMDElectromed	4.1×
NATRNatures Sunshine Products	1.3×
UTMDUtah Medical Products	1.9×
PLXProtalix BioTherapeutics	2.9×
PDEXPro DEX	4.2×
INFUInfuSystem	4.7×
VMDViemed Healthcare	2.6×
EMBCEmbecta	n/m
ARVNArvinas	0.8×
NRCNRC Health	74.1×
Peer median	2.9×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Biodesix

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.